Sun Pharma’s UNLOXCYT Gets NCCN Category 2A Preferred Status for Advanced Skin Cancer (21 Oct)

Sun Pharmaceutical Industries announced that its cancer drug UNLOXCYT (cosibelimab-ipdl) has received a Category 2A Preferred designation in updated National Comprehensive Cancer Network (NCCN) guidelines.

The recommendation covers patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who cannot undergo curative surgery or radiation.

UNLOXCYT clinical trial results

The pivotal study reported a 55% objective response rate, with 26% of patients achieving a complete response.

Fewer than 1% of patients experienced Grade 3 to 5 immune-mediated adverse reactions. No Grade 4 or Grade 5 reactions were reported during the study.

Why the NCCN designation matters

The updated designation expands UNLOXCYT’s existing Category 2A status for metastatic cutaneous squamous cell carcinoma, granted in 2025.

The drug received US FDA approval in 2024. It works by blocking PD-L1, a protein involved in suppressing immune responses against cancer cells.

Sun Pharma share returns

Period	Return
1 day	-0.90%
5 days	-0.97%
1 month	-5.96%
6 months	+2.95%
1 year	+5.06%

Sun Pharma shares gained 5.06% over one year but declined 5.96% over one month, based on the supplied market figures.

This article is for informational purposes only and is not investment advice.

What is UNLOXCYT?

UNLOXCYT (cosibelimab-ipdl) is a Sun Pharma cancer drug approved in the US for certain patients with advanced cutaneous squamous cell carcinoma.

What NCCN status has UNLOXCYT received?

UNLOXCYT received Category 2A Preferred status in updated NCCN guidelines for locally advanced cutaneous squamous cell carcinoma.

Which patients may receive UNLOXCYT?

The updated recommendation covers eligible patients with locally advanced cutaneous squamous cell carcinoma who cannot undergo curative surgery or radiation.

What was UNLOXCYT's clinical trial response rate?

The pivotal study reported an objective response rate of 55%, including a complete response rate of 26%.

What is NCCN Category 2A Preferred status?

It indicates a preferred treatment option supported by lower-level evidence and uniform NCCN expert consensus.

When did UNLOXCYT receive US FDA approval?

UNLOXCYT received US FDA approval in 2024 for certain patients with advanced cutaneous squamous cell carcinoma.

How could the NCCN designation affect Sun Pharma?

The designation could support treatment adoption and access, although the commercial impact will depend on clinical use, reimbursement and market demand.

How has Sun Pharma's share price performed?

According to the supplied data, Sun Pharma shares declined 0.90% in one day and 5.96% over one month, while gaining 5.06% over one year.

Is the NCCN designation guaranteed to increase Sun Pharma shares?

No. The designation may influence sentiment, but the share price also depends on earnings, valuation, broader market conditions and other business developments.